BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27th – 30th. The presentation will take the form of a fireside chat, which will be archived here for 90 days. Management will also be available for 1-on-1 meetings with investors. Presentation details  Date:  September 28th Time:  4pm ET Webcast: https://wsw.com/webcast/cantor12/vyne/2115540 About VYNE Therapeutics Inc.VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for…

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th – 15th. The presentation will take the form of a fireside chat, which will be available on demand here beginning September 13th at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors. Date: September 13 Time: On Demand, beginning at 7:00 AM (ET) Webcast: VYNE Fireside Chat For…

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX114 expected by year end and VYN201 and VYN202 to enter the clinic in 2022 Company has prepaid the entirety of its outstanding debt and expects to significantly reduce operating expenses Conference call and live webcast today at 8:30 am Eastern Time BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the second quarter…